Skip to main content
OpenTrials
Completed

NCT Number: NCT02082028

Efficacy of a Chronic Care Model Supported by Self Monitoring of Blood Glucose With BGStar Over Usual Care in Improving Glycemic Control in Patients With Type 2 Diabetes Not Treated With Insulin

To demonstrate the superiority of a chronic care model (SINERGIA model) supported by the Self Monitoring of Blood Glucose with BGStar over usual care in improving glycemic control at 12 months in patients with type 2 diabetes not treated with insulin.

Completed

Looking for future studies?

Notify Me

Key information

Age range

45 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Investigational Site Number 016, Andria (BA), Italy

Loading trial locations.

About this study

The planned study duration is 36 months (9 quarters). The estimated duration of screening/enrollment will be 12 months, followed by the 12-month experimental phase, plus the 12-month follow-up in the observational phase.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Males and females
  • Age ≥ 45 years
  • Type 2 diabetes
  • First access at the diabetes clinic
  • Any diabetes duration
  • HbA1c >7.0 and ≤ 9.0%
  • Already treated with any oral antidiabetic agent (OAD) or requiring the initiation of therapy with OAD
  • Patients not using SMBG or using SMBG with a frequency ≤1 test/week
  • Written informed consent

Exclusion criteria

Treatment with insulin or need to start insulin regimens or continuous sub-cutaneous insulin infusion at the first access; Refusal or inability to give informed consent to participate in the study;

Conditions / situations such as:

  • Patients with short life expectancy;
  • Patients with conditions/concomitant diseases making them non evaluable for the primary efficacy endpoint according to physician's judgment;
  • Requirement for concomitant treatment that could bias primary evaluation (i.e. corticosteroid treatment);
  • Patient is the Investigator or any Sub-Investigator, research assistant, pharmacist, study coordinator, other study site staff or relative of study site staff thus considered directly involved in the conduct of the study;
  • Current addition/abuse of alcohol or drugs;
  • Patients with any mental condition rendering them unable to understand the nature, scope, and possible consequences of the study;
  • Pregnant or breast-feeding women;
  • Patients living too far from investigational center or other conditions reducing the adherence to the protocol; Subjects unlikely or unable to comply with the Protocol requirements (e.g. illiterate, uncooperative, unable to return for follow-up visit, unable to use BGStar unlikely to complete the study)

Treatment and study plan

BGStar

Device

Glucose Meter

Device

Primary outcomes

  1. Change in HbA1c levels from baseline

    Time frame: baseline to 12 months

Secondary outcomes

  1. Percentage of participants with HbA1c ≤7.0%

    Time frame: at 12 months and 24 months

  2. Variation in body weight from baseline

    Time frame: at 12 months and 24 months

  3. Variation in waist circumference from baseline

    Time frame: at 12 months and 24 months

  4. Variation in blood pressure from baseline

    Time frame: at 12 months and 24 months

  5. Variation in lipid profile from baseline

    Time frame: at 12 months and 24 months

  6. Quality of life: SF12 (Health Survey) questionnaire

    Time frame: at 12 months and 24 months

  7. ADDQOL (Audit of Diabetes-Dependent Quality of Life)

    Time frame: at 12 months and 24 months

  8. DTSQ (Diabetes Treatment Satisfaction Questionnaire)

    Time frame: at 12 months and 24 months

  9. ABIM-14 (American Board of Internal Medicine satisfaction questionnaire)

    Time frame: at 12 months and 24 months

  10. PDM (Patient involvement in the Decision Making process) questionnaire

    Time frame: at 12 months and 24 months

  11. PHCO (Patient Health Care Orientation) questionnaire

    Time frame: at 12 months and 24 months

  12. Participants satisfaction with SMBG meter assessed by Visual Analog Scale (VAS)

    Time frame: at 12 months and 24 months

Sponsors and collaborators

Lead sponsor

Sanofi

Industry

Registry information

Official study title

Randomized Clinical Trial on the Efficacy of Self-Monitoring Blood Glucose in the Context of a Chronic Care Model for Type 2 Diabetes Patients Treated With Oral Agents Only

Acronym: SELF CARE

Important dates

Study start
2012
Primary completion
2015
Study completion
2015
First posted
Mar 7, 2014
Registry last updated
May 3, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.